DE3787793D1 - Verwendung von einem mullerischem inhibitorstoff als kontraceptivum. - Google Patents

Verwendung von einem mullerischem inhibitorstoff als kontraceptivum.

Info

Publication number
DE3787793D1
DE3787793D1 DE87904602T DE3787793T DE3787793D1 DE 3787793 D1 DE3787793 D1 DE 3787793D1 DE 87904602 T DE87904602 T DE 87904602T DE 3787793 T DE3787793 T DE 3787793T DE 3787793 D1 DE3787793 D1 DE 3787793D1
Authority
DE
Germany
Prior art keywords
mulleric
contraceptive
inhibitor
mulleric inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE87904602T
Other languages
English (en)
Other versions
DE3787793T2 (de
Inventor
Patricia Donahoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of DE3787793D1 publication Critical patent/DE3787793D1/de
Publication of DE3787793T2 publication Critical patent/DE3787793T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/811—Drug, bio-affecting and body treating compositions involving sex selection or contraception
DE87904602T 1986-06-24 1987-06-24 Verwendung von einem mullerischem inhibitorstoff als kontraceptivum. Expired - Fee Related DE3787793T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/877,735 US4753794A (en) 1986-06-24 1986-06-24 Use of mullerian inhibiting substance as a contraceptive agent
PCT/US1987/001514 WO1988000054A1 (en) 1986-06-24 1987-06-24 Use of mullerian inhibiting substance as a contraceptive agent
CA000540533A CA1321140C (en) 1986-06-24 1987-06-25 Use of mullerian inhibiting substance as a contraceptive agent

Publications (2)

Publication Number Publication Date
DE3787793D1 true DE3787793D1 (de) 1993-11-18
DE3787793T2 DE3787793T2 (de) 1994-03-24

Family

ID=25671394

Family Applications (1)

Application Number Title Priority Date Filing Date
DE87904602T Expired - Fee Related DE3787793T2 (de) 1986-06-24 1987-06-24 Verwendung von einem mullerischem inhibitorstoff als kontraceptivum.

Country Status (6)

Country Link
US (1) US4753794A (de)
EP (1) EP0271570B1 (de)
AU (1) AU600013B2 (de)
CA (1) CA1321140C (de)
DE (1) DE3787793T2 (de)
WO (1) WO1988000054A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0437427A4 (en) * 1985-10-30 1992-07-01 Biogen, Inc. Cleaved dimers of mullerian inhibiting substance-like polypeptides
US5427780A (en) * 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
US5010055A (en) * 1986-06-24 1991-04-23 The General Hospital Corporation Use of EGF to reverse the contraceptive activity of MIS
US5661126A (en) * 1989-01-19 1997-08-26 The General Hospital Corporation Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression
CA2087026A1 (en) * 1990-05-16 1992-01-11 Patricia K. Donahoe Treatment of male infertility
US5310880A (en) * 1991-04-12 1994-05-10 The General Hospital Corporation Purification of Mullerian inhibiting substance
WO1993019177A1 (en) * 1992-03-18 1993-09-30 The General Hospital Corporation FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY
US5574065A (en) * 1994-04-21 1996-11-12 Clintec Nutrition Co. Method and composition for normalizing injury response
EP1488794A3 (de) 1994-11-22 2005-04-20 Balance Pharmaceuticals, Inc. Verhütungsverfahren
US5724920A (en) * 1996-12-18 1998-03-10 Meisman; Stephen A. Animal seat belt restraint
US20020119921A1 (en) * 1999-03-31 2002-08-29 Michael Streit Thrombospondin-2 and uses thereof
EP1074265A1 (de) * 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Verwendung von AMH und/oder AMH Agonisten und/oder AMH Antagonisten zur langfristigen Regulierung von weiblicher Fertilität
US6673352B1 (en) * 1999-09-14 2004-01-06 The General Hospital Corporation Use of Mullerian inhibiting substance for treating excess androgen states
AU2001231196A1 (en) 2000-01-27 2001-08-07 The General Hospital Corporation Delivery of therapeutic biological from implantable tissue matrices
US8011661B2 (en) 2001-09-28 2011-09-06 Shuffle Master, Inc. Shuffler with shuffling completion indicator
WO2004017919A2 (en) * 2002-08-23 2004-03-04 The General Hospital Corporation Use of mullerian inhibiting substance and interferon for treating tumors
US8342525B2 (en) 2006-07-05 2013-01-01 Shfl Entertainment, Inc. Card shuffler with adjacent card infeed and card output compartments
US8353513B2 (en) 2006-05-31 2013-01-15 Shfl Entertainment, Inc. Card weight for gravity feed input for playing card shuffler
WO2011045202A1 (en) 2009-10-12 2011-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Selective antagonist or agonist of amhrii for modulating fertility
US8800993B2 (en) 2010-10-14 2014-08-12 Shuffle Master Gmbh & Co Kg Card handling systems, devices for use in card handling systems and related methods
US8485527B2 (en) 2011-07-29 2013-07-16 Savant Shuffler LLC Card shuffler
US9378766B2 (en) 2012-09-28 2016-06-28 Bally Gaming, Inc. Card recognition system, card handling device, and method for tuning a card handling device
US9511274B2 (en) 2012-09-28 2016-12-06 Bally Gaming Inc. Methods for automatically generating a card deck library and master images for a deck of cards, and a related card processing apparatus
CA2904978A1 (en) 2013-03-12 2014-10-09 The General Hospital Corporation Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases
EP3046582A4 (de) 2013-09-20 2017-05-10 The General Hospital Corporation Verwendung von modifizierten müllerschen hemmstoff (mis)-proteinen zur behandlung von neurodegenerativen erkrankungen
AU2014362307A1 (en) 2013-12-11 2016-06-30 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
US9504905B2 (en) 2014-09-19 2016-11-29 Bally Gaming, Inc. Card shuffling device and calibration method
MA41629A (fr) * 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
WO2018022292A1 (en) * 2016-07-26 2018-02-01 Trustees Of Tufts College Antibody-conjugated nanoparticles and medical uses thereof
WO2018112168A1 (en) 2016-12-14 2018-06-21 The General Hospital Corporation Mullerian inhibiting substance (mis) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4404188A (en) * 1981-07-29 1983-09-13 Massachusetts General Hospital Purified Mullerian Inhibiting Substance and method of purification
US4510131A (en) * 1981-07-29 1985-04-09 The General Hospital Corporation Purified Mullerian Inhibiting Substance and method of use
US4487833A (en) * 1982-03-01 1984-12-11 The General Hospital Corporation Method of preparing hybridomas and of purifying immunogenic materials

Also Published As

Publication number Publication date
CA1321140C (en) 1993-08-10
AU7700887A (en) 1988-01-29
WO1988000054A1 (en) 1988-01-14
EP0271570A1 (de) 1988-06-22
EP0271570A4 (de) 1989-12-19
DE3787793T2 (de) 1994-03-24
EP0271570B1 (de) 1993-10-13
AU600013B2 (en) 1990-08-02
US4753794A (en) 1988-06-28

Similar Documents

Publication Publication Date Title
DE3787793T2 (de) Verwendung von einem mullerischem inhibitorstoff als kontraceptivum.
DE3879806D1 (de) Polymerisierung von aethylen.
DE3783802D1 (de) Laufflaeche von luftreifen.
DE3676052D1 (de) Massenpolymerisation von dicyclopentadien.
FI871570A0 (fi) Utmatningsanordning foer en fraon en rulle avdragbar materialbana.
ATE32495T1 (de) Verwendung von hesperidin.
ATE55039T1 (de) Verwendung von aryloxy-verbindungen als antidots.
DE59001751D1 (de) Verwendung von di-styryl-phenyl-triglykolether als kristallisationsinhibitor.
ATE112172T1 (de) Targetformer von antitumor-methyltrithioagenzien.
DE3685258D1 (de) Verwendung von pflanzenprotoplasten.
DE3583953D1 (de) Einfuehrung von funktionellen monomeren.
DE3785689T2 (de) Verwendung von prostaglandin-biosynthese-hemmer.
ATE125794T1 (de) Prodrogen von antiinflammatorischen 3-acyl-2- oxindol-1-carboxamiden.
DE68922130T2 (de) Verwendung von 2-Methoxy-4-Propyl-1-Cyclohexanol als Duftstoff.
DE69002136D1 (de) Saccharidderivate von protocatechualdehyd.
DE3779211D1 (de) Verwendung von dihydrobenzopyranderivaten.
DE69002139D1 (de) Kosmetische verwendung von 3-indolbrenztraubensaeure.
ATE95701T1 (de) Verwendung von einem mullerischem inhibitorstoff als kontraceptivum.
FI852876L (fi) Anordning foer undervattensarbete.
DE3481403D1 (de) Verwendung von "nafazatrom".
DE68918213D1 (de) Alkylierung von Halogendisilanen.
PT73100B (de) Verwendung von propionibakterien
ATE109486T1 (de) Entfärbung von glycosiden.
ATE92755T1 (de) Phenol-thioether als inhibitoren von 5lipoxygenase.
DE68903383T2 (de) Angepasste paare von leistungsumwandlern.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee